Format

Send to

Choose Destination
Semergen. 2018 Sep;44(6):409-419. doi: 10.1016/j.semerg.2018.02.001. Epub 2018 Mar 21.

[Prostate cancer screening using prostate-specific antigen: The views of general and laboratory physicians].

[Article in Spanish]

Author information

1
Unidad de Investigación, Fundación para la Investigación Mútua Terrassa, Universitat de Barcelona, Barcelona, España; Comisión del Laboratorio Basado en la Evidencia, Sociedad Española del Laboratorio Médico (SEQC-ML), Barcelona, España; Committee of Evidence-Based Laboratory Medicine (C-EBLM), International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), Milán, Italia; Laboratorio de Toxicología, Universitat Autònoma de Barcelona, Barcelona, España. Electronic address: nuria.gimenez@uab.cat.
2
Comisión del Laboratorio Basado en la Evidencia, Sociedad Española del Laboratorio Médico (SEQC-ML), Barcelona, España; Servicio de Bioquímica y Genética Molecular (CDB), Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, España.
3
CAP Valldoreix, Fundación para la Investigación Mútua Terrassa, Universitat de Barcelona, Barcelona, España.
4
Comisión del Laboratorio Basado en la Evidencia, Sociedad Española del Laboratorio Médico (SEQC-ML), Barcelona, España.
5
Unidad de Investigación, Fundación para la Investigación Mútua Terrassa, Universitat de Barcelona, Barcelona, España; ABS Abrera, Direcció d'Atenció Primària Costa de Ponent, Institut Català de la Salut, Barcelona, España.
6
Servicio de Oncologia Radioterápica. Institut Catalá d'Oncologia (ICO), Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) (Radiobiology and Cancer), L'Hospitalet de Llobregat, Barcelona, España; Departamento de Ciencias Clínicas-Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, España.

Abstract

INTRODUCTION:

It is currently recommended to provide individualised information on benefit-risk balance and shared decision-making in prostate cancer screening using prostate-specific antigen (PSA).

AIM:

To determine the usual practice and the views of general and laboratory practitioners in the screening of prostate cancer using PSA.

MATERIAL AND METHODS:

A cross-sectional study based on a questionnaire and on PSA screening requests from Primary Health Care (PHC) in men older than 49 years with no prostatic symptoms.

RESULTS:

In 2015, PHC in Catalonia requested PSA on 15.2% of males. A total of 114 general practitioners and 227 laboratory practitioners participated in the questionnaire. The mean age of those who responded was 43 years with a mean of 17 years' experience, and included 64% women. According to general practitioners, 61% of PSA was performed at the patient's request. The uncertainty score when requesting PSA was 5 points for general practitioners and 5.7 for laboratory professionals. Interest in having clinical recommendations received 7.2 points in PHC, and 8.8 in the laboratory. Knowledge about the different clinical practice guidelines received was less than 5 points overall.

CONCLUSIONS:

General practitioners requested PSA screening in almost one-sixth of men over the age of 49 without prostate disease, often at the patient's request, and after informing them of the benefits and risks. PHC and laboratory physicians were interested in having recommendations and information, although they did not usually consult clinical practice guidelines immediately.

KEYWORDS:

Antígeno prostático específico; Atención primaria; Cribado; Cuestionarios; Cáncer de próstata; Laboratorio; Laboratory; Primary Health Care; Prostate-specific antigen; Prostatic neoplasm; Questionnaires; Screening

PMID:
29574008
DOI:
10.1016/j.semerg.2018.02.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center